Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer
Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer
复制标题
DOI：
10.1007/s12094-016-1485-1
复制
发表时间：
2016-11-01
影响因子：
3.4
通讯作者：
Mandel, N. M.
中科院分区：
文献类型：
--
作者：
Selcukbiricik, F.;Kanbay, M.;Mandel, N. M.
贝伐单抗是一种抗血管内皮细胞生长因子的单抗。它模糊了肿瘤组织的血管形成，损害了肿瘤内的微循环。肿瘤内微循环受损导致组织缺氧，导致尿酸水平升高。本研究的主要目的是探讨尿酸变化与贝伐单抗治疗反应之间的关系。这项研究包括158名接受贝伐单抗治疗的转移性结直肠癌患者。男性100例(63.3%)，女性58例(37.7%)。中位年龄61岁(29-83岁)。3个月尿酸水平升高与病情稳定有关(P<；0.001)。尿酸水平升高的患者总体存活率显著增加(p<；0.001)。癌胚抗原水平的下降与尿酸水平有关(p<；0.022)。总之，这项研究首次显示对贝伐单抗化疗有良好反应的转移性结直肠癌患者的血尿酸显著升高。但进一步的研究证明，监测尿酸水平是否可以预测转移性结直肠癌患者的临床结果是合理的。
Bevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation leads to tissue hypoxia and results in increase of uric acid level. The main aim of our study was to investigate the relationship between uric acid change and response to bevacizumab therapy. This study included a total of 158 patients with metastatic colorectal cancer who had received bevacizumab therapy. The number of male patients was 100 (63.3 %) while female patients number was 58 (37.7 %). The median age was 61 (29-83). There was relationship between increase of uric acid level of third month uric acid level and stable disease (p < 0.001). There was a significant overall survival increased in the group with increased uric acid level (p < 0.001). The decline of CEA level was related to uric acid level (p < 0.022). In conclusion, this study is the first showing significant increases of serum uric acid in patients with metastatic colorectal cancer who favorably responded to chemotherapy with bevacizumab. But further studies are justified to test whether monitoring uric acid levels might predict clinical outcomes of patients with metastatic colorectal cancer.